Custom Shots and Drug Cocktails

Recent advancements in dermatology focus on combination therapies and personalized medicine. The mRNA melanoma vaccine, specifically the Keynote 942 study, demonstrates improved recurrence-free survival when combined with pembrolizumab, though recent phase 3 press releases lack detailed peer-reviewed data. Hidradenitis suppurativa treatment shows promise with dual immunomodulator therapy, specifically combining biologics with JAK inhibitors like upadacitinib, which significantly reduced IHS and pain scores in refractory cases. Furthermore, atopic dermatitis management benefits from adding methotrexate to upadacitinib for therapy-resistant patients, leveraging the extensive safety database of JAK inhibitors and methotrexate to achieve clinical remission without significant additive immunosuppression. These strategies highlight a shift toward aggressive, multi-modal approaches for managing severe, refractory skin conditions, emphasizing the efficacy of combining established biologics with targeted small-molecule inhibitors to overcome treatment resistance.